The growth factor transforming growth factor alpha (TGFa) and the nuclear transcription factor c-myc often are overexpressed by human breast cancer cells. To produce models of breast disease with these etiologies, mice were generated that carried TGF-a-or c-mycencoding transgenes. Transgene targeting employed the whey acidic protein (WAP) gene promoter, which is expressed in pregnant and lactating mammary epithelial cells. Non-virgin WAP-TGFa transgenic mice displayed accelerated mammary development during pregnancy, delayed post-parturient mammary involution, a progressive increase in the number of hyperplastic alveolar nodules (HANs), and development of mammary carcinoma with a mean latency of 9 months. Non-virgin WAP-c-myc transgenic mice displayed accelerated mammary gland development during pregnancy and development of mammary carcinomas with a latency of 8 months. Bitransgenic mice carrying both WAP-TGFa and WAPc-myc displayed a dramatic acceleration of tumor development. These models identify the overexpression of TGFa or c-myc as etiological factors in the development of mammary neoplasia and demonstrate the increased severity of disease when both molecular alterations are present in the same cell.
Introduction
Transgenic technology, in which foreign genes are introduced into an animal genome, provides a means to speci®cally target expression of a selected gene to a selected type of cell. The resulting genetically modi®ed animals then can be used to precisely identify the relationship between altered gene expression and subsequent changes in cell structure, function, or growth characteristics. The transgenic approach has been used extensively to study the role of certain genes in the pathogenesis of disease, including cancer. This review describes our use of transgenic mice to assess the consequences of overexpression of a growth factor, transforming growth factor alpha (TGFa), and a transcription factor, c-myc, in mammary epithelium (Sandgren et al., 1995) . Overexpression of either or both genes is identi®ed commonly in human breast cancer, making selection of these genes for analysis particularly relevant to the study of disease in humans.
TGFa and c-myc in human breast cancer
TGFa was isolated from conditioned medium of murine sarcoma virus transformed cells and was named transforming growth factor alpha due to its growth promoting activity on NRK ®broblasts and its ability to reversibly induce a transformed phenotype (de Larco and Todaro, 1978) . Later, TGFa was identi®ed in normal tissues of the rodent embryo (Derynck, 1992) and in human tissues (Christensen and Poulsen, 1996) . TGFa belongs to a family of ligands that bind to one or several members of the epidermal growth factor receptor (EGFR) family (reviewed by Lee et al., 1992 Lee et al., , 1995 Kumar et al., 1995) . It is produced as a transmembrane protein from which the active 50 amino acid peptide is cleaved at the extracellular surface. In addition, there is evidence that the transmembrane precursor has biological activity (Wong et al., 1989; Brachmann et al., 1989) . Typically, EGFR binding initiates a signal for the cell to divide.
Most primary breast tumors display EGF family receptors and secrete EGF-like growth factors. TGFa is the most commonly identi®ed EGF-like growth factor in primary breast tumors as evidenced by the presence of TGFa mRNA and/or protein in 30 ± 70% of cases reported (reviewed in Rudland et al., 1995) . In addition, overexpression of TGFa in the mammary gland of transgenic mice is potently oncogenic (Sandgren et al., 1990 (Sandgren et al., , 1995 Jhappan et al., 1990; Matsui et al., 1990; Halter et al., 1992; Smith et al., 1995) , and coexpression of TGFa with other oncogenes shortens tumor latency (Sandgren et al., 1995; Amundadottir et al., 1995 Amundadottir et al., , 1996 Muller et al., 1996; Davies et al., 1999) .
The c-myc gene is one of three members of the MYC family. Each member encodes a nuclear transcription factor that regulates the expression of other genes by binding to the speci®c DNA sequence CACGTG. The c-myc protein regulates expression of multiple target genes associated with mammary epithelial growth and death responses (reviewed in Dubik et al., 1996; Nass and Dickson, 1997) , suggesting a pivotal role for c-myc in balancing cell cycle progression with apoptosis. c-Myc was one of the ®rst proto-oncogenes to be identi®ed as overexpressed in breast tumors and has been found to be ampli®ed in 15 ± 40% breast tumors. In addition, identi®cation of increased c-myc activity in primary tumors suggests a poor prognosis (reviewed in Berns et al., 1996; Nass and Dickson, 1997) .
A role for c-myc in breast cancer also has been suggested by studies in transgenic mice. Mice that overexpress c-myc in the mammary gland are predisposed to develop mammary neoplasia (Stewart et al., 1984; Leder et al., 1986; Andres et al., 1988; Oncogene (2000) 19, 1092 ± 1096 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: EP Sandgren Schoenenberger et al., 1988; Sandgren et al., 1995) . Furthermore, as for TGFa, co-expression of c-myc with growth factors or other oncogenes increases the incidence of tumors and shortens their latency (Sinn et al., 1987; Andres et al., 1988; Sandgren et al., 1995; Amundadottir et al., 1995 Amundadottir et al., , 1996 Jager et al., 1997; McCormack et al., 1998) .
TGFa-induced mouse mammary cancer
The rationale for selection of TGFa in these studies was based upon the prevalence of TGFa overexpression in human neoplasms, as described above. Our targeting strategy employed the mouse whey acidic protein (WAP) gene regulatory elements ( Figure 1 ). The WAP gene directs mammary epithelial-speci®c transgene expression that is upregulated at mid-pregnancy, and expression typically is maintained throughout lactation (Pittius et al., 1988; Bayna and Rosen, 1990) . A variable population of mammary epithelial cells in the non-pregnant female also express the transgene (Santarelli et al., 1996) , and this is most evident during estrus (Robinson et al., 1995) .
TGFa proved to be a potent transforming agent in mouse mammary gland. The following lesion pathogenesis was observed in three examined lineages of WAP-TGFa transgenic mice maintained in the (C57BL/66SJL)F2 strain background (Sandgren et al., 1995;  Table 1 ). (1) During mid to late pregnancy, mammary alveolar proliferation and dierentiation were accelerated (Figure 2a,b) , so that by day 18 of pregnancy (parturition occurs at day 20) the transgenic mouse gland resembled a day 1 lactating nontransgenic mouse gland. However, transgenic glands generally were not functional, so that females failed to lactate and nourish their young. (2) Following parturition and removal of pups, mammary involution was delayed in transgenic versus non-transgenic female mice (Figures 2d,e) . Some alveolar structures failed entirely to involute and persisted within the mammary fat pad. (3) Persistent alveolar structures, or hyperplastic alveolar nodules (HANs), increased in number with successive pregnancies (Figure 2f ). After ®ve or more pregnancies, mammary fat pads in most transgenic mice displayed greater than 100 HANs, which often became con¯uent. These structures resembled normal alveoli, though typically displayed hyperplasia and variable dysplasia relative to normal non-transgenic alveoli. (4) At a mean age of 9.5 months in the best-characterized line, non-virgin WAP-TGFa transgenic female mice required sacri®ce due to the development of mammary neoplasms. Most neoplasms were glandular to microcystic carcinomas (Figure 2g ), resembling HANS, but much larger. Fibroadenomas (Figure 2h ) and solid and papillary carcinomas (Figure 2i ) also were observed. Although lung metastasis was uncommon, most neoplasms were transplantable. Despite widespread expression of TGFa throughout the mammary epithelium, the neoplasms that developed were focal and relatively few in number. This observation indicated that TGFa expression was not sucient to transform these target cells. Interestingly, endogenous cyclin D1 expression was upregulated in many TGFainduced neoplasms, but other genetic alterations could not be identi®ed (Sandgren et al., 1995) . Penetrance of the neoplastic phenotype in parous mice was 100%. Virgin females and males were not aected.
c-Myc-induced mouse mammary cancer
Rationale and construct design (Figure 1) for generation of c-myc overexpressing transgenic mice were the same as for TGFa. c-Myc also was a potent mammary epithelial transforming agent, but lesion pathogenesis diered from that for TGFa (Sandgren et al., 1995;  Table 1 ). (1) Alveolar development was accelerated during late pregnancy in WAP-c-myc transgenic female mice, but epithelial cells appeared poorly dierentiated and the hyperplastic epithelium contained multiple dead cells (Figure 2c ). Postparturition involution was not delayed, nor were persistent alveolar nodules observed after pregnancy.
(2) At a mean age of 8 months, non-virgin WAP-cmyc transgenic mice required sacri®ce due to the development of mammary neoplasms. Most neoplasms were glandular (Figure 2j ) to solid ( Figure  2k ) carcinomas, all were transplantable, and 20% of the tumor-bearing WAP-c-myc transgenic mice displayed grossly visible lung metastases. As for TGFa, neoplasms were focal, indicating the need for additional alterations prior to the emergence of neoplasia from the c-myc transgene-expressing mammary epithelium. Penetrance of the neoplastic phenotype was 100%. Again, virgin mice and males were not aected.
Synergistic interaction between TGFa and c-myc
Interestingly, bitransgenic mice carrying both WAPTGFa and WAP-c-myc transgenes displayed a more severe disease (Sandgren et al., 1995;  Table 1 ). Mammary epithelium became severely hyperplastic during mid-to late-pregnancy, and diusely failed to regress following parturition. Mean time to sacri®ce due to development of multiple mammary neoplasms was less than 4 months. Neoplasms grew rapidly, were poorly dierentiated (Figure 2l ), all were transplantable, and 30% of bitransgenic female mice displayed gross evidence of lung metastases. In addition, males and virgin females also developed neoplasms. These ®ndings underscore the striking cooperativity between the secreted peptide growth factor TGFa and the nuclear transcription factor c-myc during the process of mammary carcinogenesis in vivo, suggesting a poorer prognosis for patients with neoplasms overexpressing both. Recent studies WAP-TGFa transgenic mice have been employed by other investigators to study the eects of TGFa on mammary gland development (Robinson et al., 1996 (Sandgren et al., 1995) . First, both TGFa and c-myc are potently oncogenic when overexpressed in mammary epithelium. Second, based on a comparison between these models of the natural history of disease, and in particular the distinctive character of the lesions that develop in each, it appears that the mechanisms of transformation dier for TGFa and c-myc. Third, these genes demonstrate cooperativity during neoplastic transformation of mammary epithelium; more generally, by using appropriate intercrossing strategies, these models permit direct assessment of the nature of interactions between overexpression of TGFa or c-myc and any other de®ned genetic lesion that can be engineered into mice. There currently are two principal limitations to the use of these mice. First, they cannot be used easily to study the pathophysiological interactions between oncogenes and ovarian hormones. Experimental manipulation of hormone levels results in concurrent changes in the level of transgene expression by virtue of the hormonal responsivity of the WAP gene promoter. Thus, hormone-mediated changes in tumor pathogenesis could be the result of oncogene/hormone interactions, direct modulation of transgene expression, or both, and dierentiating among these possibilities may not be possible. This limitation applies to transgenic lineages employing any of the currently characterized mammary-speci®c promoters. A second limitation involves model validation: how can we translate information provided by these models into an understanding of the disease in humans? This is a dicult question also facing all models. The answer must involve careful analysis of intermediate and late stage lesions to identify networks of changes in gene structure and expression that together constitute the molecular pathogenesis of transgene-initiated disease.
Comparison of these changes in mice with molecular changes detected in human breast cancer should provide the link between each model and a corresponding sequence of lesions that develop in humans.
